Best Place To BuildThis team manipulates genes to create LIFE from SCRATCH!? | BP2B: Student Edition! Ep.02
CHAPTERS
- 0:00 – 0:25
Space biomanufacturing vision: making medicines on Mars
The episode opens with a striking example of synthetic biology applied to space: producing essential drugs in a Martian colony. The team frames the motivation—transporting materials is expensive, so biology could become an on-site manufacturing platform.
- •Goal of producing medicines in extraterrestrial environments
- •Example target: paracetamol production using algae
- •Space logistics as a driver for synthetic biology innovation
- 0:25 – 1:32
What iGEM is and why it matters at IIT Madras
The host introduces the Student Edition format and meets the iGEM IIT Madras team lead. They explain iGEM as a global synthetic biology competition where student teams build real-world solutions using engineered biology.
- •iGEM stands for International Genetically Engineered Machine
- •Annual international competition with undergrad and postgrad teams
- •Problem-solving focus: real-world challenges via synthetic biology
- •IIT Madras as one of the few Indian institutes with an iGEM team
- 1:32 – 1:59
Synthetic biology explained: engineering bacteria like systems
The team breaks down synthetic biology as genetic engineering with an engineering mindset—treating cells as programmable systems. They explain how new genes and genetic circuits can be introduced to make organisms produce desired outputs.
- •Synthetic biology closely related to genetic engineering
- •Engineering mindset: bacteria as a controllable system
- •Genetic circuits and gene insertion to produce target products
- •Design goal: make cells do useful, predictable work
- 1:59 – 3:03
Real-world success story: insulin made by engineered E. coli
A concrete application is used to clarify how engineered organisms help humans: insulin production. The conversation corrects a common misconception—bacteria manufacture insulin in a lab, and the product is extracted and processed into medicine.
- •Insulin as a flagship synthetic biology application
- •Insulin gene inserted into E. coli for production
- •Insulin is extracted and post-processed (not injected bacteria)
- •Cells as ‘manufacturing hubs’ for therapeutics
- 3:03 – 3:48
How iGEM projects are chosen: freedom, research, and stakeholder input
The team explains that iGEM doesn’t impose a single prompt—students pick their own problem statement each year. Their process involves literature review, speaking with stakeholders, and designing a synthetic biology solution worth building and presenting.
- •Complete freedom in selecting the yearly problem statement
- •Literature research to identify meaningful challenges
- •Stakeholder outreach across domains to validate problems
- •Track record and competitive motivation (gold medals mentioned)
- 3:48 – 5:12
Orientation goals and recruiting: enthusiasm over prior biology
Just before and after the orientation, the leads describe what the session is designed to do: introduce newcomers to the field and the team’s work. They emphasize that strong biology background isn’t required—curiosity and drive are the key filters.
- •Orientation introduces synthetic biology and current iGEM work
- •Recruitment targets freshers and early-year undergrads
- •No prerequisite biology expertise—enthusiasm is the main requirement
- •Applications come later once next project groundwork is set
- 5:12 – 7:48
Interdisciplinary iGEM roles: dry lab, WebOps, media, and outreach
The discussion broadens beyond lab biology to show iGEM’s interdisciplinary structure. Students from any department can contribute through modeling, software, wiki/web development, media, and human practices, making iGEM a blend of research and product-style delivery.
- •iGEM is not only for biotech students
- •Dry lab and software contributions are central
- •WebOps builds the wiki as a key competition deliverable
- •Media and communications roles support impact and outreach
- 7:48 – 11:24
Inside the lab: the 2025 project on gene regulation via epigenetics
In the biotech lab space, the team outlines their 2025 focus: increasing expression of protein targets through gene regulation. They describe a novel epigenetic approach—using methylation marks guided by a CRISPR-dCas-based system to influence transcription and boost output.
- •Gene regulation concept: DNA → RNA → protein and ‘overexpression’ goals
- •Epigenetics via methylation as regulation without changing DNA sequence
- •CRISPR-dCas targeting + methylation-related attachment for site-specific marking
- •Applications: scaling enzymes/metabolites for therapeutics and manufacturing
- 11:24 – 13:17
How methylation can increase expression: transcription-factor access and output
The host presses on the “how,” prompting a clearer explanation of mechanism. The team describes methyl groups as structural/marker cues that affect transcription-factor binding, driving more RNA copies and ultimately more protein—useful for mass production of scarce compounds.
- •Methylation can modify DNA structure and binding behavior
- •Transcription factors bind and increase RNA transcription rates
- •More RNA leads to more protein production downstream
- •Biomanufacturing payoff: higher yields of valuable metabolites
- 13:17 – 19:41
Wet lab walkthrough: bacterial transformation from sterile hood to colonies
A wet-lab member demonstrates the core procedure used across projects: bacterial transformation. The sequence covers sterility (laminar flow), making cells competent, heat-shock style steps, recovery in LB broth, plating on agar, and reading colonies as clonal populations.
- •Transformation = introducing circular DNA (plasmids) into bacteria
- •Laminar airflow hood for sterile microbial handling
- •Competent cells + ice/42°C steps enable DNA uptake
- •Recovery in LB broth, then plating on agar to grow colonies
- •Colonies represent clonal descendants of a single cell
- 19:41 – 23:09
Team operations and resourcing: subteams, funding, and mentorship
The team explains how iGEM is organized to execute quickly: wet lab, computational/dry lab, and WebOps, with shared responsibility for sponsorship and human practices. They also describe corporate sponsorship as the main funding source and the role of professors and PhD students in guiding protocols.
- •Team structure: wet lab, computational modeling/software, WebOps
- •~30 members with defined subteam sizes
- •Funding primarily via corporate sponsorship (AstraZeneca as title sponsor)
- •Faculty and PhD mentorship for protocols and lab skill development
- •Work across prokaryotic and mammalian (eukaryotic) systems
- 23:09 – 27:07
Careers, AI acceleration, and the ethics line in synthetic biology
The closing section covers what students do after iGEM and where the field is heading—especially AI-enabled modeling to reduce experimental burden. It ends with ethical responsibilities: biosafety, containment, bioterrorism awareness, and deciding when not to publish work that could be misused.
- •Post-iGEM paths: biotech research, consulting, software, interdisciplinary fields
- •Example interdisciplinary frontier: organ-on-a-chip
- •Next frontier: AI/computation to simulate biology and speed discovery
- •Ethics focus: biosafety, contamination control, containment strategies
- •Dual-use risk: considering nefarious misuse and withholding publication when necessary
